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PERSPECTIVES IN CLINICAL NEPHROLOGY
Treatment of the nephrotic syndrome associated with
primary glomerulonephritis
The term nephrotic syndrome (NS) refers to a condition
characterized by heavy proteinuria, hypoalbuminemia, edema and
hyperlipidemia. The NS is often seen when the urinary protein
excretion exceeds 3.5 g/day and is almost invariably present when
proteinuria is greater than 5 glday. In the NS there may be a
constellation of biochemical and clinical abnormalities that can
predispose to disabling and even fatal complications, such as
infections, bone disease, arterial or venous thrombosis, cardiovas-
cular disease, etc. In addition, the onset of NS is a marker for bad
outcome for most glomerular diseases.
The NS may be caused by a large variety of renal diseases. In
this paper, however, we will limit ourselves to reviewing the
treatment for those cases of NS associated with primary glomer-
ulonephritis.
Immunomodulating therapy
Some immunomodulating agents, such as corticosteroids, cyto-
toxic drugs and cyclosporin, may induce remission of proteinuria
and protect renal function in at least some subgroups of primary
glomerulonephritis. Unfortunately, all these agents have a low
therapeutic index. Thus, in deciding whether, how, and when to
use immunomodulating drugs, the nephrologist should be aware
of their potential side effects, of the results that may be obtained
in the different subgroups of glomerulonephritis, and of the
possible strategies for maximizing their therapeutic index.
Minimal change disease
Minimal change disease (MCD) accounts for more than 80% of
cases of NS in children, but may also occur in adulthood and in the
elderly. Clinically, MCD is characterized by a pure, often severe
NS. Proteinuria may persist for many years and eventually disap-
pears. The renal prognosis is excellent, except for a few patients
who develop focal and segmental glomerular sclerosis with possi-
ble progression to renal failure. However, a few children may die
from complications related to the NS or its treatment. The
prognosis seems to be worse in adults [1], and even more in
patients who are older than 60 years [2], with several patients
dying from infection, oligoanuria, thrombotic or cardiovascular
complications.
According to Brodehl [3] the three main objectives in treating
MCD are: (1) to induce remission of the NS as soon as possible in
order to prevent the severe complications related to the nephrotic
state; (2) to prevent the relapses of NS; and (3) to avoid iatrogenic
side effects in a disease which can run a long relapsing course.
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Corticosteroids are the drug of choice for the initial treatment
of MCD. Proteinuria disappears in more than 90% of children
during an eight week course of prednisone, given at a dose of 60
mg/m2/day for four weeks, followed by 40 mg/m2/48 hr for four
other weeks [4]. In about half of the patients, remission occurs
within one week and most of the other children remit within four
weeks. Unfortunately, many patients have relapses of NS after
remission. The rate of relapses seems to be influenced by the
duration of the initial treatment. About 80% of children relapse
within one year when prednisone is given for four weeks, 60%
relapse after an eight week treatment and only 36% relapse when
prednisone is given for 12 weeks [3]. Adults are usually treated
with an initial attack dose of prednisone of 1 mg/kg/day. Only 50
to 60% of them become free of proteinuria within eight weeks.
However, if corticosteroid therapy is given up to 28 weeks,
complete remission may be obtained in 80% of patients [2]. As for
children, the duration of initial treatment influences the risk of
relapse. A controlled study showed that adults treated with
prednisone for two to three months had more relapses than those
given alternate-day prednisone for one year. As a consequence,
the cumulative dosage of steroids was greater for the patients
given short-term prednisone [5]. According to these data, to
reduce the risk of relapse the initial treatment should be pro-
longed. It is also advisable to taper off prednisone gradually, not
abruptly, in order to avoid a rebound effect which may cause
exposure to relapses. In children we suggest starting with 60
mglm2/day of prednisone until disappearance of proteinuria for
three consecutive days. Then the patient may be switched to
alternate day prednisone, 40 mg/m2/48 hr for at least 12 weeks,
with subsequent tapering off of prednisone by 5 to 10 mg/m2/48 hr
every month, Most children respond within four weeks, but the
response may be delayed in a few patients. Thus we prolong
prednisone administration for 8 to 12 weeks before considering a
child as steroid-resistant. We treat adults with prednisone, 1
mg/kg/day, either until remission or for at least six weeks if there
is no complete response. After that, the patient is switched to
alternate day prednisone, starting with 1.6 mg/kg/48 hr, and
reducing the dose by 0.2 to 0.4 mgfkg/48 hr every month. Since
some few adults enter remission after several weeks, we give
prednisone at decreasing doses for four to six months before
considering an adult as a non-responder. It is preferable to give
prednisone in a single morning dose, between 7 and 9 a.m., in
order to reduce the side effects. Of course, this schedule should be
tailored for individual patients. Prednisone is stopped earlier if an
intercurrent infection or any steroid-related complication occurs.
For the elderly patient who may have contraindications for
high-dose prednisone, the initial treatment may consist of cyclo-
phosphamide (2 mg/kg/day) or chlorambucil (0.15 mg/kg/day) for
8 to 12 weeks.
After remission from the initial episode of NS some 20 to 30%
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Table 1. Comparison of the main side effects of cyclophosphamide and
chlorambucil
Agranulocytosis
It is dose-related. At equivalent doses, the risk is similar for the two
agents. Rare if the daily doses do not exceed 2 mg/kg/day for
cyclophosphamide or 0.15 mg/kg/day for chlorambucil.
Gonadal toxicity
The risk of azoospermia is greater for chiorambucil. Irreversible
azoospermia may develop after a cumulative dosage of more than
10 mg/kg for chlorambucil [17] or of 300 mg/kg for
cyclophosphamide [18].
Bladder toxicity
The excretion in the urine of acrolein, a metabolite of
cyclophosphamide, can lead to hemorrhagic cystitis, bladder fibrosis
and even cancer. A forced diuresis may reduce the risk of bladder
toxicity. This complication does not develop with chlorambucil.
Mutagenicity and oncogenicity
In patients with connective tissue diseases cyclophosphamide induces
more chromosome damage than chlorambucil [19]. Both alkylating
agents can expose to an increased risk of cancer, particularly
lymphoma and acute leukemia. The risk is mainly related to their
cumulative dosage. In patients with non-malignant disease who
developed malignancy, the mean dosage of cyclophosphamide was
more than 80 g [20]—about 3 mg/kg/day for 380 days in a patient
weighting 70 kg—the mean cumulative dosage of ehlorambucil was
7 g [21]—about 0.2 mg/kg/day for 500 days for a patient of 70 kg.
of patients remain without proteinuria. A similar proportion of
patients, with variations depending on the type and duration of
the initial therapy, has fewer than two relapses every six months.
The relapse is usually as steroid-responsive as the first episode of
NS. Unlike the first attack, however, the intensity and the duration
of treatment do not influence the subsequent rate of relapses [6].
Spontaneous remission may occur but it is impossible to predict
which patient will remit spontaneously and which will not. Some
authorities suggest starting treatment early [31; others, however,
prefer to wait 7 to 10 days to avoid a useless corticosteroid
administration to those patients who will remit spontaneously.
The standard treatment consists of 60 mg/m2/day (up to a
maximum of 80 mg/day) for children and of 1 mg/kg/day for
adults. This dosage is given until the urine is protein-free for three
consecutive days. Then prednisone may be given every other day
for four weeks, at a dose of 40 mg/m2/48 hr for children and of
0.75 mg/kg/48 hr for adults, The maximum duration of prednisone
administration for patients who do not respond early should be
similar to that of the first episode.
Patients with two or more relapses within six months after the
first episode or three or more relapses within 12 months are called
frequent relapsers. Patients who relapse within 14 days after
stopping the steroid or when the dosage is reduced are called
steroid-dependent. Treatment of these patients is difficult since
prolonged corticosteroid therapy may produce side effects, such as
hypertension, psychiatric disorders, osteoporosis, obesity, diabe-
tes, cushingoid features, infections, growth retardation, etc. Cy-
clophosphamide or chiorambucil can significantly reduce the rate
of relapses in these patients. The results of cytotoxic therapy
clearly depend on the duration of treatment. Barratt et al [7]
compared the effects of two weeks and eight weeks of cyclophos-
phamide in steroid-sensitive patients with relapsing NS and
concluded that the longer-term therapy was far more effective.
Rance, Arbus and Balfe [8] reported a 27% rate of remission at
one year for children given cyclophosphamide for fewer than six
Table 2. Recommendations for the use of CsA in patients with primary
glomerulonephritis
Do not give CsA to patients with established renal insufficiency, severe
hypertension and/or tubulointerstitial lesions in the renal biopsy;
The starting dose of CsA should not exceed 5 mg/kg per day for adults
or 100—150 mg/rn2 per day for children;
If no response is observed within 3 months, CsA should be stopped
(probably ineffective);
Plasma creatinine, blood pressure and blood CsA should be monitored
(compliance, bioavailability, drug interference);
The dose of CsA should be reduced if plasma creatinine rises by more
than 30% over the basal value;
Nephrotoxic drugs should be avoided;
Interactions of drugs which might interfere with CsA metabolism should
be taken into account;
The maintenance dose should be the lowest effective one;
After 2 years CsA may be tapered off gradually to see whether the
patient remains in remission
weeks, while 66% of patients were still in remission when treat-
ment was extended for 12 weeks. On the other hand, while too
short a therapy is of little benefit, prolonged administration of
alkylating agents can increase the risk of severe side effects. To
prevent any major side effects in MCD, many clinicians now
administer cyclophosphamide or chlorambucil for not more than
eight weeks. With this duration of therapy, almost 70% of
frequent relapsers maintain remission with time, but most steroid-
dependent patients relapse soon after the treatment is stopped
[9]. However, if cyclophosphamide is given at a dose of 2
mg/kg/day for 12 weeks instead of 8 weeks, about 2/3 of steroid-
dependent children remain in remission after two years [10]. This
cumulative dose is below the estimated threshold of risk for
azoospermia (Table 1). Cyclosporin A (CsA) is another alterna-
tive to steroids. Most steroid-dependent patients can be main-
tained in remission with CsA, which is usually started after
remission has been induced with steroids [11—13]. After the drug
is stopped, early relapses occur in many but not in all patients [11].
These relapses seem to be less likely to occur if CsA is given long
term and if it is tapered off gradually. The safety and tolerability
of CsA in idiopathic NS was investigated in 661 patients enrolled
in 10 studies [14]. Hypertrichosis (18%), gum hyperplasia (16%),
gastrointestinal symptoms (11%) and hypertension (9%) were the
most frequent non-renal side effects. Out of 225 patients with
MCD treated with CsA, three developed end-stage renal failure.
All of them were steroid- and CsA-resistant, suggesting that the
unfavorable evolution was caused by an underlying focal and
segmental glomerular sclerosis rather than being a nephrotoxic
effect of CsA. In the other patients the mean levels of serum
creatinine at the last follow-up did not differ significantly from
basal values. It can be argued, however, that serum creatinine is
not the most appropriate measurement to monitor renal function
in patients given a potentially nephrotoxic drug. As a matter of
fact, CsA may induce histological lesions even in patients with
perfectly normal kidneys. Cases of interstitial fibrosis have been
reported in patients given CsA because of non renal autoimmune
diseases [15]. In MCD, Niaudet et al [13] took control renal
biopsies from 43 children, 2 to 19 months after the initiation of
CsA. In 13, extension of tubulointerstitial lesions was seen in spite
of the fact that impaired creatinine clearance was detected in only
one. Thus, some caution is needed when using CsA (Table 2).
In summary, there is no standard treatment for patients with
frequent relapses or with steroid dependency. We suggest the
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following algorithm (Fig. 1). Since cyclophosphamide or chloram-
bucil may obtain stable remission in a good number of cases, it is
worthwhile to give first a short course of one of these agents (8
weeks to frequent relapsers, 12 weeks to steroid-dependent
patients). Cyclophosphamide, at a dose of 2 mg/kg/day, is less
gonadotoxic and may be preferred for children and for young
adults. Chiorambucil, which is perhaps more efficacious [161 and is
less toxic to the bladder, may be used for the other patients, at a
dose of 0.15 mg/Kg/day (Table 1). If the NS relapses, the patients
should not be treated again with alkylating agents, since their
toxicity is cumulative. Usually these patients respond well to
steroids. Among the various possible schedules, alternate-day
prednisone is the most widely used and may be given safely for
several months. Should any signs of hypercorticism appear, the
steroid may be stopped and replaced by CsA. If the patient
remains in remission, CsA may be reduced after 6 to 12 months by
25% every two months, to determine the minimal effective dose.
Several investigators continue CsA therapy for years. We prefer to
gradually stop CsA after two years. If the patient relapses, we treat
her/him again with steroids for 6 to 12 months and then again with
CsA for one to two years, in order to prevent the potential toxicity
of prolonged administration of either drug.
Some 10% of patients with a histological diagnosis of MCD do
not respond to the standard regimens with steroids. Most of them,
sooner or later, show picture of focal and segmental glomerular
sclerosis in renal biopsies and should be treated accordingly.
Focal and segmental glomerular sclerosis
Focal and segmental glomerular sclerosis (FSGS) is a hetero-
geneous clinicopathological entity which may complicate several
diseases or morbid conditions. In its idiopathic form, FSGS is
usually associated with the NS. Most nephrotic patients tend to
progress to end-stage renal failure within 10 years after the clinical
onset. The renal outcome of FSGS is similar in children and in
adults, although children may sometimes show a better response
to therapy. The presence of tubulointerstitial lesions at renal
biopsy is a marker of a bad renal prognosis, while the prognostic
role of glomerular lesions, such as hilar lesions, mesangial prolif-
eration and collapsing glomeruli is still under discussion.
There are not controlled prospective trials with the use of
corticosteroids or cytotoxic agents in this disease. The available
literature is mostly based on retrospective studies, and it is
possible that some papers reporting negative results have not been
published. The general impression is that only a small minority of
patients with FSGS and NS achieve complete remission of
proteinuria with a short course of high-dose prednisone. On the
basis of this poor response, many clinicians are reluctant to treat
patients with FSGS. However in a retrospective survey of the
literature Schena and Cameron [22] reported that more than 40%
of patients given corticosteroids and/or cytotoxic drugs versus
none of untreated patients entered complete or partial remission.
Moreover, 37% of treated patients versus 25% of untreated
patients maintained normal renal function at the end of follow-
ups of various lengths. Some studies have reported good results
with prolonged therapies. A French study reported that 69% of
nephrotic patients had complete remission after 6 to 12 months of
prednisone [23]. Pei et al [24] reported that 40% of nephrotic
patients treated with prednisone for at least six months attained
complete remission. At 12 years, 96% of responders still had
stable renal function while all the non-responding or non-treated
patients had some degree of renal insufficiency. Mendoza et al
[25] treated 23 children with intravenous methylprednisolone
pulses plus oral prednisone, 2 mg/kg/48 hr for 78 weeks. When no
response was obtained, cytotoxic agents were added. After a mean
follow-up of 55 months, 18 patients were without NS and only one
had progressed to renal failure. In spite of the very aggressive
approach side effects were relatively mild in that particular series.
We reviewed the outcome for 59 patients with FSGS and NS
treated either with prolonged steroid treatment (27 patients) or
with long-term immunosuppressive therapy (13 patients) or with
corticosteroid and cytotoxic agents, alternated every other month,
for six months (19 patients). After a mean follow-up of 75 months,
Cyclophosphamide
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Well
tolerated
Relapse
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treatment Fig. 1. Suggested therapeutic approach for patients
with minimal change ditease either frequently
relapsing or steroid-dependent.
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31 patients (52%) were in complete remission, 4 were in partial
remission, 6 were still nephrotic and 16 had progressed to renal
failure. Patients who responded did so after a median period of
five months. There were no differences in the rates of response for
the three groups of treatment, but more than 50% of patients
given steroids alone versus fewer than 20% of patients treated
with immunosuppressive agents relapsed after remission. Fewer
than 3% of patients who had initially responded to therapy
developed renal failure within 10 years versus 65% of non-
responders [26].
CsA is also being used to treat FSGS. A review of the literature
showed that some 40% of patients may be maintained without NS
under CsA [27]. It is unclear, however, whether CsA impairs or
protects renal function in FSGS. Some studies reported worsening
of histological lesions in several patients treated with CsA [12, 13],
but it is difficult to know whether renal lesions became aggravated
because of the progression of FSGS or because of CsA-related
nephrotoxicity. In an Italian controlled trial [281, patients with NS
who did not respond to steroids were randomly assigned to
symptomatic therapy or to be given CsA (5 mg/kg/day for adults
and 6 mg/kg/day for children) for six months, then tapered off by
25% every two months until complete discontinuation. In the first
year, 32% of CsA-treated patients entered complete remission
and another 27% had partial remission, while only 16% of
untreated controls had partial remission of NS. The mean levels of
creatinine clearance for the two groups did not differ.
We think that for nephrotic patients with FSGS the first
approach should consist of high-dose prednisone (60 mg/m2/day
for children, 1 mg/kg/day for adults) for two months in order to
recognize the few responders. For those patients, the subsequent
treatment may be similar to that of MCD, including the manage-
ment of possible relapses. What to do with non-responders is
controversial. Many clinicians are against treatment but the
available data indicate that a more prolonged treatment may
obtain remission of NS and maintain renal function stable in at
least 50% of patients. We are, therefore, in favor of a further
therapeutical trial for patients who do not respond to the two-
month prednisone treatment, provided that they do not present
particular contraindications to therapy. We suggest the following
algorithm (Fig. 2). Unless steroid toxicity develops, after the first
two months prednisone may be continued every other day in
tapering doses for another four to six months. Alternatively, a
therapeutic protocol alternating corticosteroids with a cytotoxic
agent for six months may be used, similar to the one we use for
membranous nephropathy [29]. With such a schedule we obtained
10 complete remissions in 19 patients with FSGS and NS [26]. If
NS persists, in spite of either treatment, we switch the patient to
CsA, unless renal function and/or blood pressure are abnormal or
unless interstitial fibrosis is present at renal biopsy. If no remission
is observed within three months, that patient will be unlikely to
respond later and CsA should be stopped. For patients who
respond, we gradually taper CsA after some months in order to
identify the minimal effective dosage. After one to two years of
treatment, a renal biopsy is considered to rule out histological
lesions caused by CsA.
Membranous nephropathy
Membranous nephropathy (MN) is the most frequent cause of
NS in adults. Its eventual outcome is not easily predictable. Some
nephrotic patients maintain normal renal function and may even
have spontaneous remission of NS, while 30 to 50% progress to
end-stage renal failure within 10 years from clinical Onset, The
persistence of heavy proteinuria [30] and/or the presence of
tubulointerstitial lesions [29] in the initial renal biopsy are the
factors more often associated with a progressive deterioration of
renal function. On the other hand, patients who attain a complete
remission of proteinuria generally have excellent renal prognosis
even in the long-term [31].
There are conflicting results for the use of corticosteroids in
MN. An American study reported better chances of remission of
NS and better preservation of renal function for nephrotic
patients randomly assigned to prednisone, 125 mg/m2/48 hr for
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two months, than for untreated controls [321, These results,
however, were not confirmed by an English controlled trial where
the same regimen was tested in a larger number of patients
followed for at least three years [33]. In a Canadian study
nephrotic and non-nephrotic patients with MN were randomly
assigned to supportive treatment or to prednisone, 40 mglm2/48
hr, for six months [34]. No difference between the two groups
could be seen in either the rate of remission or the mean
creatinine clearance. Controlled trials with cytotoxic agents also
gave conflicting results although generally showing a favorable
effect on proteinuria [35—37]. Unfortunately, however, these stud-
ies were performed on too small numbers of patients. A combi-
nation of corticosteroids with a cytotoxic agent was assessed in an
Italian controlled trial [29]. Patients with MN and NS were
randomly assigned to supportive therapy or to methyipred-
nisolone (1 g for 3 days intravenously, then 0.4 mg/kg day orally
for 1 month) alternated every other month with chlorambucil (0.2
mg/kg/day for 1 month) for six months. There were more remis-
sions of NS in patients given the combined treatment (81% vs.
33%), and these often occurred after the end of the therapeutic
course. After a median follow-up of five years, there were more
treated patients still without NS (67% vs. 23%). The mean slope
of the reciprocal of plasma creatinine was also significantly better
for the treated than for the untreated group. In another Italian
study, patients with MN and NS were randomly assigned to either
combined treatment with methylprednisolone and chlorambucil
for six months, as in the previous trial, or to methylprednisolone
alone given for six months (1 g intravenously for 3 days at month
1, 3, 5 and 0.4 mg/kg/48 hr orally for 6 months) at the same
cumulative dosage as in the other arm [38]. After a mean
follow-up of 54 months, 64% of the patients given combined
therapy versus 38% of patients given corticosteroids alone were
without NS. No significant difference between the two groups was
seen in the mean reciprocal of plasma creatinine up to four years.
In both studies, fewer than 10% of patients had to stop combined
treatment because of side effects. No disquieting late morbidity
has been seen up to now in patients given chlorambucil.
In summary, there is some evidence that MN may be treatable,
but how to manage patients with NS is still controversial. Some
physicians think that MN naturally has a favorable course and give
only symptomatic treatment [39]; others are concerned of the
potential toxicity and prefer to use corticosteroids alone [40]; still
others use a combined regimen with corticosteroids and an
alkylating agent [291. Tobetter define the possible evolutions with
these different attitudes, Piccoli et al [41] recently evaluated the
results of the two Italian trials previously mentioned by decision
analysis. Assuming triple probabilities and costs for methylpred-
nisolone plus chiorambucil complications compared to methyl-
prednisolone, with no risk for supportive therapy, referring to an
average 40-year-old patient, and using the quality-adjusted life
expectancy year as the utility scale, they found that with methyl-
prednisolone plus chiorambucil the difference in expected quality-
adjusted life expectancy was 7.2 years compared to supportive
treatment, and 2.6 years compared to methyiprednisolone. To
offset the longer survival obtained with methylprednisolone plus
chlorambucil versus methyiprednisolone, all patients treated with
methylprednisolone plus chlorambucil should undergo either fatal
(5% vs. 0.3% with methylprednisolone) or non-fatal complica-
tions (95% vs. 15% with methylprednisolone). This threshold
denotes a great stability of the inequality in the expected quality-
adjusted life expectancy. Consequently these data seem to support
choosing a treatment with methyiprednisolone or with methyl-
prednisolone plus chiorambucil if one considers their side effects
a suitable trade-off for a five or seven quality-adjusted life
expectancy years respectively longer survival. Only an absurd
increase in death rate with methylprednisolone plus chlorambucil
could offset the difference. On the basis of the available data we
suggest the following algorithm for nephrotic patients with normal
renal function (Fig. 3). According to the clinical conditions of the
patient and the conviction of the physician, one can start with
either symptomatic therapy, or corticosteroids alone or methyl-
prednisolone and chlorambucil. In case of remission no further
treatment is given. Untreated patients with persisting NS or with
progressive renal dysfunction may be offered either a six month
treatment with corticosteroids or with methylprednisolone and
Diagnosis of idiopathic
Membranous nephropathy
A B C
4 4;No Response
response
No Relapse
relapse
Symptomatic
therapy
Remission Persisting NS
or renal
insufficiency
V
Treat
with
A or B
Fig. 3. Treatment of membranous nephropathy
with nephrotic syndrome. Dotted lines indicate
the different possible options.
600 Ponticelli and Passerini: Nephrotic syndrome
chiorambucil. For patients who relapse, the response to retreat-
ment (either with steroids alone or combined with chiorambucil)
is similar to that observed after the first course. For patients with
severe NS who do not respond to either treatment, a trial with
CsA may be done. Rostoker et al [42] reported that 4 of 15
nephrotic patients with MN treated with CsA entered complete
remission and another 7 had partial remission. NS relapsed only
in 3 of 9 patients in whom CsA was stopped.
When to start treatment is also a matter of debate. Some
clinicians suggest waiting at least one to two years after clinical
onset of NS in order to avoid treatment of those patients who
might remit spontaneously. Others even wait until renal insuffi-
ciency develops. We prefer to start treatment early, for several
reasons: (i) an effective therapy prevents the possible complica-
tions of NS; (ii) the probability of response is better for patients
who do not yet have advanced glomerular or tubulointerstitial
lesions; (iii) therapy is better tolerated by patients with normal
renal function; and (iv) patients with an already established renal
insufficiency may fail to respond to therapy or their response may
be incomplete.
What to do for patients with declining renal function? First, all
efforts should be made to recognize and appropriately treat any
possible superimposed complication, such as venous thrombosis
(echocolordoppler, cavography), interstitial nephritis (drug his-
tory, eosinophilia, eosinophiluria, rash, fever, renal biopsy), ex-
tracapillaiy glomerulonephritis (nephritic sediment, rapid deteri-
oration in renal function, renal biopsy). What type of treatment
may be used in patients with progressive renal failure? Short et al
[40] reported some improvement of renal function with the use of
high dose intravenous steroid pulses followed by alternate-day
prednisone. Good results have been reported after one to two
years of azathioprine or cyclophosphamide associated with low-
dose prednisone [43—45] or a six month course with methyipred-
nisolone and chlorambucil [46]. Two small controlled trials in
patients with renal insufficiency are available. Falk et al [47] did
not find differences between patients randomly assigned to be
given intravenous pulses of cyclophosphamide every month for six
months or alternate-day prednisone for two months. Reichert,
Koene and Wetzels [48] found a significantly better kidney
survival in patients assigned to receive methylprednisolone and
chlorambucil for six months than in those given monthly intrave-
nous pulses of cyclophosphamide for six months. When compared
to other schedules with cytotoxic drugs, the six month treatment
with steroids and chlorambucil has the advantage of giving a
cytotoxic agent for only three months. We are therefore in favor
of such a treatment in patients with renal insufficiency. We suggest
however, that the dosage of chlorambucil should not exceed 0.1
mg/kg/day, since the side effects are increased in patients with
renal insufficiency.
IgA mesangial nephritis
This disease is probably the most common form of glomerulo-
nephritis. It occurs at any age but it is more common in the second
and the third decade. IgA mesangial nephritis (IgAN) usually runs
a slowly progressive course, with development of end-stage renal
failure within 20 years in about 20 to 50% of patients [49]. Heavy
proteinuria, extended glomerular sclerosis and diffuse interstitial
fibrosis are usually associated with a poor renal outcome.
NS is uncommon in IgA nephritis and is usually associated with
a poor prognosis. However, some few patients with NS, who show
no or minimal glomerular changes in the renal biopsy, generally
respond well to corticosteroids and have a fair outcome [50, 51].
For the other nephrotic patients, the biopsy usually shows mod-
erate to severe mesangial proliferation often associated with
advanced chronic lesions or focal glomerulosclerosis. Might im-
munomodulating therapy alter the course of the disease in these
cases? Some retrospective studies reported good results with
corticosteroids. However, in a randomized trial there were no
differences in the final creatinine clearance between nephrotic
patients assigned to symptomatic therapy and those given pred-
nisone for four months. A good proteinuria response was seen
only in steroid-treated patients with mild mesangial proliferation
[51]. In another controlled trial, patients were assigned to CsA or
supportive therapy [52]. CsA reduced the amount of proteinuria
but caused a more rapid decline of renal function than in the
untreated patients. Schena, Montenegro and Scivittaro [49] per-
formed a meta-analysis of eight studies involving 196 IgAN
patients. Patients with heavy proteinuria, whether or not associ-
ated with the NS, benefitted from the administration of cortico-
steroids and/or cytotoxic drugs, as 67% of treated patients had
complete or partial remission of proteinuria versus 34% of
untreated patients. Moreover 36% of treated patients progressed
to renal failure versus 59% of the untreated patients. These data
support active treatment for patients with heavy proteinuria, who
are those at higher risk for developing renal failure. Unfortu-
nately, the treatments considered in the meta-analysis were quite
variable, so that it is difficult to ascertain which is the best therapy
for these patients. Recently, Rostoker et a! [53] reported a
significant reduction of proteinuria and a stopping in decline of
renal function in 11 adults with severe IgA nephropathy treated
with high-dose immunoglobulins for three months.
In summary, patients with IgAN and NS with pictures of MCD
in the renal biopsy usually respond well to steroids and should be
managed like those having MCD (see above). There are no
definite data in favor of a specific treatment for the other cases of
NS, so that the choice between abstensionism and intervention is
optional. Should one decide to try therapy, we would suggest a
six-month course with alternate-day prednisone (1 mg/kg/48 hr),
which is usually well tolerated. A special group of patients shows
rapid impairment of renal function and superimposed extracapil-
lary GN is found at biopsy. For these patients, who are destined to
develop end-stage renal failure within a short time, we feel that an
aggressive treatment is justified. Three to five daily intravenous
methylprednisolone pulses (1 g each) followed by oral prednisone
(1 mg/kg/day for 1 to 2 months, then gradually tapered off over 6
to 12 months) and cyclophosphamide (2 mg/kg/day for 2 to 4
months) may obtain partial recovery of renal function for some
patients. For the more resistant cases, methylprednisolone pulses
may be repeated if the clinical condition of the patient allows it.
Unfortunately, it is not unusual for slowly progressive renal
insufficiency to develop after an initial improvement of renal
function.
Membranoproliferative glomerulonephritis
Idiopathic inembranoproliferative glomerulonephritis (MPGN)
is an infrequent cause of glomerular disease in both children and
adults. The disease can affect patients at any age, but it usually
occurs in ages of between 8 and 30 years. MPGN can be divided
into types I, II, III on the basis of different patterns in light
microscopy, immunofluorescence and electron microscopy, but
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the prognoses and courses of these different types are similar. The
renal prognosis is usually bad for patients with renal insufficiency
and/or NS at presentation. More than 50% of patients with NS
progress to end-stage renal failure within 10 years after clinical
onset [54]. In general the disease is more severe in adults.
As for other glomerulonephritides, treatment is controversial.
For many years the group of McEnery, McAdams and West [55]
have been emphasizing the beneficial role of prolonged high-dose
alternate-day prednisone (2 to 2.5 mg/kg/48 hr) in MPGN. They
reported renal survival of 90% at nine years for 45 children with
MPGN treated for several years with such a regimen. In spite of
the prolonged administration, steroids were well tolerated by most
patients. However, their results were less exciting for the 15
patients with overt NS at presentation. End-stage renal failure
developed in four of them within five years, and another child
became uremic after eight years [55]. A controlled study with a
similar regimen organized for the International Study of Kidney
Disease in Children concluded that alternate-day steroid therapy
may actually slow the rate of progression of type I MPGN, but
long-term treatment was associated with severe hypertension and
seizures in several patients [56]. Other non-controlled studies
reported good results with indomethacin plus low-dose cyclophos-
phamide or with mixtures of cytotoxic, anticoagulant and anti-
platelet agents. However, in a randomized trial there were no
differences in the mean proteinuria and in the decline of renal
function between 27 patients treated for 18 months with cyclo-
phosphamide, coumadin and dipyridamole and 32 controls [57].
In another controlled study, Donadio and Offord [54] reported
that in patients with type I MPGN a combination of aspirin (975
mg/day) and dipyridamole (225 mg/day) lowered the rate of renal
failure up to four years, but analysis at 10 years showed no
difference in renal survival between treated (49%) and untreated
patients (41%).
In summary, the treatment of MPGN remains elusive. Symp-
tomatic therapy and a good control of arterial hypertension are
cornerstones of importance. These measures can provide a 10
year patient survival, similar to that expected for the general
population [54]. In the case of the nephrotic patient who usually
has a bad renal prognosis, a course of steroids may be tried. In
such a case the earlier the treatment the better the results [55].
We suggest a treatment with alternate-day prednisone at a dose of
2.0 mg/kg/48 hr for two months, with gradual decrease in the
following period. If no response is observed within four to six
months, the steroid should be stopped. If there is considerable
reduction of proteinuria the steroid may be continued at the
minimal effective dose. Some patients with MPGN may show a
rapidly progressive decline in renal function, sometimes triggered
by an infection of by a drug exposure. A renal biopsy should be
obtained for these cases. In the presence of an extracapillary
glomerulonephritis or of a superimposed interstitial nephritis, an
aggressive treatment with intravenous high-dose methyipred-
nisolone pulses, oral prednisone and cyclophosphamide may
obtain a substantial recovery of renal function in several patients.
Supportive therapy
The management of nephrotic patients must take into consid-
eration not only the specific pharmacological approach to the
underlying glomerular disease, but also the supportive measures
aimed at preventing and treating the clinical sequelae of massive
proteinuria. This supportive therapy is of most importance for
those patients who do not respond to immunomodulating agents
and are therefore exposed to the complications of prolonged NS.
Dietetic measures
The intake of sodium should be restricted to around 2 g per day
to reduce the positive sodium balance. From a practical point of
view, it is generally sufficient to recommend not adding salt to the
diet. Severe salt restriction is necessary only for patients who
respond poorly to diuretics. In the past a high protein intake was
prescribed to compensate for the urinary protein loss. This,
however, increases glomerular permeability to macromolecules,
which results in a further increase in proteinuria while the protein
balance remains negative and low serum albumin levels persist
[58]. On the other hand, studies with the low-protein diets have
given conflicting results. Reduced urinary albumin excretion and
increased serum albumin levels have been reported by some
investigators [59], while others did not find any reduction in
proteinuria, at least in MN [60]. As we await the results of
long-term trials we feel reasonable to abandon the prescription of
a high protein diet in NS while recommending a diet containing
about 1 g/kg/day of protein. A lipid-lowering diet (less than 200
mg per day of cholesterol, total fat less than 30% of total calories,
and polyunsaturated fatty acids about 10% of total calories) is
usually prescribed for patients with hypercholesterolemia. How-
ever, individual responses to this diet are difficult, if not impossi-
ble, to predict, ranging from minimal to 15 to 20% decreases in
low-density lipoprotein cholesterol levels. Moreover, the stricter
the regimen the worse the compliance, especially in the long-term.
Therefore it is difficult to handle the nephrotic hyperlipidemia by
diet alone. Recently, a vegetarian diet based on soy and supple-
mented with essential amino acids has been shown to be more
effective in reducing hyperlipidemia than the traditional lipid
lowering diet. Some decrease in proteinuria was also observed
[61]. However no data are available about the long-term compli-
ance, efficacy and tolerance of such a diet.
Edema
Edema which does not respond to restriction of the dietary
sodium intake often requires diuretic therapy. The first step may
consist of administration of a thiazide agent, preferably in com-
bination with a potassium-sparing drug, such as amiloride, triam-
terene or spironolactone. Many patients, however, particularly
those with anasarca, volume overload, or pulmonary congestion
do not respond to thiazides. Loop diuretics such as furosemide,
ethacrinic acid or bumetamide are needed for these cases. Among
these agents, furosemide is the most widely used because of its
good tolerance even at very high doses. Furosemide may be given,
either intravenously or by mouth, at doses ranging from 25 to
2,000 mg per day, according to the severity of edema and the
response to therapy. Since binding of the drug to tubular fluid
albumin can impair the response, high doses of furosemide are
often needed to overcome the blunting effect of this binding [62].
In patients refractory to ioop diuretics as monotherapy, combina-
tion with diuretics acting at different levels than furosemide, such
as hydrochlorothiazide (25 to 50 mg per day) or metolazone (2.5
to 10 mg per day), may maximize the diuretic response. During
diuretic treatment, the patients must be monitored to detect
possible complications, such as hypokalemia, metabolic alkalosis
or severe intravascular depletion.
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Hypoalbuminemia and proteinuria
Administration of i.v. albumin to nephrotic patients is an
expensive procedure and increases renal albumin clearance with
only a small transient increase in the plasma albumin concentra-
tion. Aibumin infusion may be justified only for cases with severe
symptomatic plasma volume depletion with hypotension.
Some drugs may reduce the urinary loss of proteins. Inhibitors
of angiotensin converting enzyme (ACE) can have important
antiproteinuric effect. Although blood pressure lowering and
postglomerular vasodilation theoretically might contribute to the
antiproteinuric effect of ACE inhibitors, the effect is more prob-
ably related to changes in glomerular permeability to macromol-
ecules [63]. The antiproteinuric effect of ACE inhibitors depend
on the dose, the duration of treatment and the sodium intake.
Heeg et al [64] reported that 5 mg of lisinopril decreased
proteinuria by 27%, while 10 mg of lisinopril reduced proteinuria
by up to 63%. In most patients, important and stable reduction of
proteinuria occurred only after several weeks. The best antipro-
teinuric effect was observed with a dietary sodium intake of 50 to
100 mEq/day, and it was completely abolished when the salt intake
was 200 mEq/day. Treatment with ACE inhibitors is usually well
tolerated but some patients may develop anemia, hypotension or
dry cough. In rare cases there is impairment of renal function,
more often in patients with renal artery stenosis. In practice, to
maximize the antiproteinuric effect of ACE inhibitors the patient
should first be told to follow a low-salt intake diet. The ACE
inhibitor should be started at low doses to test the tolerance.
Doses should be increased progressively to the maximum toler-
ated dosage. Treatment should be prolonged for several weeks
before assessing its effectiveness.
Non-steroidal antiinflammatory drugs (NSAID5) may reduce
proteinuria by 50% or more [64—66]. This effect can be attributed
to a reduction of glomerular capillary permeability to protein, to
a decrease in intraglomerular capillary pressure, and/or to a
reduction of the filtration surface aren. In the majority of patients,
the effect is rapid (within 1 week) and reverses after cessation of
treatment. Indomethacin (150 mg/day) and meclofenamate (200
to 300 mg/day) are the two agents used most frequently. Unfor-
tunately, NSAIDs are not easy to handle in renal patients. These
agents can cause hyperkalemia and in sodium-retaining states
such as NS they can further aggravate sodium retention, reduce
the response to diuretics and impair arterial hypertension. Most
importantly NSAIDs may cause hemodynamically-mediated acute
renal failure, acute interstitial nephritis or chronic renal damage.
Thus, careful monitoring of renal function is mandatory during
treatment of nephrotic patients. NSAIDs should not be given if
the creatinine clearance is lower than 50 mI/mm.
Recently, a six-week treatment with high-dose n-3 polyunsatu-
rated fatty acids was shown to be able to reduce proteinuria by
about 30% without important side effects [67].
Hyperlipidemia
For many patients with NS, diet is not sufficient to correct
hyperlipidemia. Various lipid-lowering drugs such, as probucol,
nicotinic acid, resins, fibric acid derivates and, more recently,
hydroxymethylglutaryl coenzyme A (HUM C0A) reductase inhib-
itors, have been used in NS. Probucol is not very effective, and
may reduce not only LDL but also HDL lipoproteins. Nicotinic
acid may effectively reduce all circulating atherogenic lipoproteins
levels. However, in its rapid-release formulation it causes unpleas-
ant cutaneous vasodilation; flushing is a minor consideration with
the slow-release formulation but gastric irritation and hepatotox-
icity are frequent, even at moderate doses. Resins are unpleasant
to take, frequently cause abdominal symptoms and may interfere
with the absorption of fat-soluble vitamins and of other drugs.
Fibric acid derivates, such as clofibrate, bezafibrate and gemfibro-
zil, are more effective in lowering triglycerides (which may be
normal in NS) than cholesterol. In nephrotic patients clofibrate
may induce rhabdomyolysis and acute renal failure [68]. More-
over, these agents may expose to the risk of myopathy and of
gallstones.
At present, HMU-CoA inhibitors, such as lovastatin, pravasta-
tin and simvastatin, are considered as the drugs of choice for
treating the hyperlipidemia of NS. These agents inhibit the
rate-limiting enzyme in cholesterol biosynthesis. In nephrotic
patients, HMG-CoA inhibitors produce significant decreases in
serum cholesterol (36%), low density lipoprotemns (43%) and
apolipoprotein B (30%) levels [69, 70]. Triglycerides may also be
decreased. Although these alterations in lipoprotein composition
appear to be favorable, the strickingly elevated levels of athero-
genic lipoprotein(a) were not influenced by HMG-CoA inhibitors
[71]. Treatment with HUM CoA inhibitors is generally well
tolerated by nephrotic patients. There may be a mild and transient
increase in serum transaminase during the first months of therapy.
Myositis and myalgia are rare, but it is wise to check creatine
phosphokinase regularly.
Hypercoagulabilily
Thromboembolism is a serious and common complication of
the NS. Anticoagulant drugs can reduce the risk of thrombosis but
since they carry a substantial risk of major hemorrhagic compli-
cations, their use is generally restricted to some situations at
increased risk for thrombosis such as prolonged bed rest, surgery,
episodes of dehydration, or during the administration of intrave-
nous high-dose corticosteroids. Recently, however, decision anal-
ysis studies showed that the benefits of prophylactic anticoagula-
tion outweigh the risk at least in nephrotic patients with MN, who
are particularly exposed to the risk of intravascular thrombosis
[72, 73}. When to stop the treatment is still unclear. Since the risk
of thrombosis remains elevated until NS persists, anticoagulation
may theoretically be continued until remission or even lifelong.
Such a prolonged anticoagulation is imperative for those patients
who had two or more episodes of thrombosis or a single life-
threatening episode.
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